BURLINGAME, Calif.–(BUSINESS WIRE)–Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm,” announced that a manuscript describing his budget impact model for treating patients hospitalized with COVID-19 is available at medRxiv (link). These findings underscore the importance of selecting theRead More →